Werewolf Therapeutics, Inc.

NasdaqGS:HOWL Stok Raporu

Piyasa değeri: US$108.4m

Werewolf Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Werewolf Therapeutics yıllık ortalama 20.9% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19% annual. Gelirler yılda ortalama 67.6% oranında büyüyor .

Anahtar bilgiler

20.9%

Kazanç büyüme oranı

82.2%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı67.6%
Özkaynak getirisi-51.7%
Net Marj-578.8%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

Jul 31
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Jul 01

Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Jun 04
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 04

Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Feb 07
Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

Jan 19
Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Dec 09
There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Sep 30
Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 13
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

May 06
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Jan 27
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

Oct 24
We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Jul 08
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Mar 24
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Dec 09
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Gelir ve Gider Dağılımı

Werewolf Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGS:HOWL Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 249-54220
31 Mar 2416-42220
31 Dec 2320-37220
30 Sep 2326-37210
30 Jun 2325-41210
31 Mar 2321-50220
31 Dec 2216-54220
30 Sep 229-60200
30 Jun 224-62190
31 Mar 220-115180
31 Dec 210-202160
30 Sep 210-205125
30 Jun 210-1971010
31 Mar 210-127714
31 Dec 200-28617

Kaliteli Kazançlar: HOWL şu anda kârlı değil.

Büyüyen Kar Marjı: HOWL şu anda kârlı değil.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: HOWL kârlı değildir, ancak son 5 yılda zararlarını yılda 20.9% oranında azaltmıştır.

Büyüme Hızlandırma: HOWL 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: HOWL kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -2.3% ) karşılaştırılması zorlaşıyor.


Özkaynak Getirisi

Yüksek ROE: HOWL hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -51.65% ) sahiptir.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin